Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal

Autoimmunity Reviews

Volumn 8, Issue 3, 2009, Pages 274-280

  Caporali, Roberto ^a   Pallavicini, Francesca Bobbio ^a   Filippini, Matteo ^b   Gorla, Roberto ^b   Marchesoni, Antonio ^c   Favalli, Ennio Giulio ^c   Sarzi Puttini, Piercarlo ^d   Atzeni, Fabiola ^d   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Rheumatology and Clinical Immunology Unit   (Italy)

^c UOC Day Hospital of Rheumatology   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti tumour necrosis factor (TNF); Disease modifying anti rheumatic drugs (DMARDs); Methotrexate (MTX); Rheumatoid arthritis (RA)

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART FAILURE; HEPATITIS B; HISTOPLASMOSIS; HUMAN; INSULIN RESISTANCE; LISTERIOSIS; LUNG ASPERGILLOSIS; MEDICAL PRACTICE; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT CONTRAINDICATION; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG COSTS; DRUG TOXICITY; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; ITALY; MONITORING, PHYSIOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58749116632     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.11.003     Document Type: Review

References (40)

1. O'Dell J. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350 (2004) 2591-2602
2. Choi E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
3. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., MacFarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of antitumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
4. Gupta S., and Gollapudi S. Molecular mechanisms of TNF-alpha-induced apoptosis in naive and memory T cell subsets. Autoimmun Rev 5 (2006) 264-268
5. van Gestel A.M., Anderson J.J., van Riel P.L., Boers M., Haagsma C.J., Rich B., et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 26 (1999) 705-711
6. van der Heijde D.M., van Riel P.L., Nuver-Zwart I.H., Gribnau F.W., and van de Putte L.B. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1 (1989) 1036-1038
7. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
8. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
9. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
10. Weisman M.H. Progress toward the cure of rheumatoid arthritis? The BeSt study. Arthritis Rheum 52 (2005) 3326-3332
11. van Vollenhoven R.F. Switching between biological agents. Clin Exp Rheumatol 22 (2004) 819-836
12. Smolen J.S., Aletaha D., Weisman M.H., and Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370 (2007) 1861-1874
13. Kievit W., Fransen J., Oerlemans A.J.M., Kuper H.H., vd Laar M.A.F.J., de Rooij D.J.R.A.M., et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized control trials and clinical practice. Ann Rheum Dis 66 (2007) 1473-1478
14. Sokka T., and Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 48 (2003) 313-318
15. Zink A., Strangfeld A., Schneider M., Herzer P., Hierse F., Stoyanova-Scholz M., et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54 (2006) 3399-3407
16. Wolfe F., and Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford) 44 (2005) 18-22 (Suppl 4): iv
17. Kremer J.M., Gibofsky A., and Greenberg J.D. The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 20 (2008) 123-130
18. Valesini G., Montecucco C., and Cutolo M. Anti-TNF treatment for rheumatoid arthritis. Clin Exp Rheumatol 24 (2006) 413-423
19. Askling J., and Dixon W. The safety of anti-tumor necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 20 (2008) 138-144
20. Desai S.B., and Furst D.E. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 4 (2006) 757-790
21. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
22. Tubach F., Ravaud P., Salmon-Ceron D., Petitpain N., Brocq O., Grados F., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 43 (2006) 95-100
23. Zein N.N. Etarnercept Study Group. Etanercept as an adjuvant to interferon and ribavarin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
24. Geborek P., Baldstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphoma. Ann Rheum Dis 64 (2005) 699-703
25. Carmona L., Descalzo M.A., Perez-Pampin E., Ruiz-Montesinos D., Erra A., Cobo T., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists. Ann Rheum Dis 66 (2007) 680-685
26. Jacobsson L.T., Turesson C., Nilsson J.A., Petersson I.F., Lindqvist E., Saxne T., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 670-675
27. Jacobsson L.T., Turresson C., Gulfe A., Kapetanovic M.C., Petersson I.F., Saxne T., et al. Treatment with tumour necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1213-1218
28. Atzeni F., Doria A., Carrabba M., Turiel M., and Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 6 (2007) 529-536
29. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
30. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
31. St. Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
32. van der Heijde D., Klareskog L., Rodriguez-Valverde V., Codreanu C., Bolosiu H., Melo-Gomes J., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54 (2006) 1063-1074
33. Taylor P.C., Steuer A., Gruber J., McClinton C., Cosgrove D.O., Blomley M.J., et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 54 (2006) 47-53
34. Allaart C., Breedveld F., and Dijkmans B. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol 34 Suppl 80 (2007) 25-33
35. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146 (2007) 406-415
36. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
37. Smolen J.S., Han C., van der Heijde D., Emery P., Bathon J.M., Keystone E., et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54 (2006) 716-722
38. Hjardem E., Ostergaard M., Podenphant J., Tarp U., Andersen L.S., Bing J., et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Ann Rheum Dis 66 (2007) 1184-1189
39. Quinn M.A., Conaghan P.G., O'Connor P.J., Karim Z., Greenstein A., Brown A., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 27-35
40. P. Sarzi-Puttini, M. Antivalle, A. Marchesoni, E.G. Favalli, R. Gorla, M. Fillipini, et al. Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). Reumatismo in press.